Heart Failure & Transplant

Heart failure care has been rebuilt around four-pillar guideline-directed medical therapy, with new agents extending the toolkit across the LVEF spectrum. Sessions examine HFrEF, HFmrEF and HFpEF management, rapid-titration protocols, finerenone and vericiguat integration, GLP-1 receptor agonists in obesity-driven phenotypes, and iron repletion strategies. Advanced therapy topics span LVADs, mechanical circulatory support, donation-after-circulatory-death heart transplantation, and the expanding multi-organ heart-kidney population. Cardiomyopathy-targeted therapy includes mavacamten, aficamten and the rapidly evolving ATTR-CM landscape.